#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Basal cell naevus syndrome Prolymphocytic leukaemia Hepatitis B Thrombotic thrombocytopenic purpura Chronic myeloid leukaemia Osteosarcoma recurrent Glioma Synovial sarcoma recurrent Nephroblastoma Cholestatic pruritus Extraskeletal ossification Chronic hepatitis B Osteosarcoma metastatic Frostbite Neuronal ceroid lipofuscinosis More trials…

    Learn about Rare Diseases

    Mantle cell lymphoma stage IV – Basic Information Ehlers-Danlos syndrome Synovial sarcoma recurrent – Life with Disease Ewing’s sarcoma Hereditary motor and sensory neuropathy – Basic Information Angiosarcoma recurrent – Diagnostics Waldenstrom’s macroglobulinaemia recurrent – Life with Disease Advanced systemic mastocytosis – Life with Disease Isodicentric chromosome 15 syndrome – Life with Disease Hepatoblastoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Atogepant Secukinumab Trientine Dihydrochloride Ruxolitinib Miglustat Delandistrogene Moxeparvovec Transpocart19 Isatuximab SRSD107 Fluvastatin Sodium Bi 764524 Eliglustat Tartrate Cytisine VOTOPLAM Minzasolmin Fludeoxyglucose (18F) Vanzacaftor Betula Pendula Pollen Extract Ribociclib Ianalumab More therapies…

    Learn about Your Condition

    Postpartum haemorrhage Delirium Osteochondrodysplasia Anal incontinence Eye disorder Breast cancer recurrent Immune-mediated renal disorder Tympanic membrane perforation Melanoma recurrent Chondrosarcoma metastatic Asthmatic crisis Immunosuppression Otitis media Large cell lung cancer Schizophreniform disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Study on the Effectiveness of Entrectinib and Other Drug Combinations for Patients with Advanced Solid Tumors, Multiple Myeloma, or Non-Hodgkin Lymphoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Prolymphocytic leukaemia
    • Non-Hodgkin’s lymphoma
    • Plasma cell myeloma
    Investigated Drugs:
    • Dabrafenib
    • Dacomitinib
    • Erdafitinib
    The Netherlands

  • Study on the Safety and Effectiveness of BGB-11417 Alone and with Dexamethasone, Carfilzomib, Daratumumab, or Pomalidomide for Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Dexamethasone Acetate
    • Carfilzomib
    France Germany Greece Italy Spain

  • Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Ciltacabtagene Autoleucel
    • Bortezomib
    • Daratumumab
    Belgium Czechia France Germany Greece The Netherlands +3

  • Study on HUVR-CARTemis-1 Therapy for Patients with Relapsed Multiple Myeloma After Allogeneic Transplant Using a Drug Combination

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Autologous Peripheral Blood-Derived Cd4 And Cd8 T Lymphocytes, Transduced With A Lentiviral Vector To Expressing A Chimeric Receptor Against Bcma With Co-Stimulatory Sequences 4-1-Bb And Cd3 Zeta
    • Dexchlorpheniramine
    • Allopurinol
    Spain

  • Study on the Safety and Effectiveness of AZD0305 Alone and with Other Cancer Drugs for Adults with Relapsed or Refractory Multiple Myeloma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Azd0305
    • Dimethyl Fumarate
    • Elranatamab
    France Germany Spain

  • Study on the Safety and Effects of CC-92480 with Dexamethasone and Drug Combinations for Patients with Relapsed or Refractory Multiple Myeloma

    Recruiting

    1 1 1 1
    Investigated Drugs:
    • 2-(3-(3,5-Dimethyltriazol-4-Yl)-5-((S)-Oxan-4-Yl(Phenyl)Methyl)Pyrido(3,2-B)Indol-7-Yl)Propan-2-Ol
    • Mezigdomide
    • Tazemetostat
    Norway Spain
Previous Page
1 … 4 5 6 7 8 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!